Home > Healthcare > Medical Devices > Therapeutic Devices > Stents Market

Stents Market Trends

Report ID: GMI3372
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Stents Market Trends

Increasing number of coronary artery disease and peripheral vascular disorders globally will positively impact stent industry growth.

Growing number of patient pool with chronic disease will drive the demand for percutaneous coronary intervention and peripheral vascular procedures. According to report published by Centers for Disease Control and Prevention (CDC) in 2020, coronary heart disease is the most common type of heart disease, killing 382,820 people. About 20.1 million adults aged 20 and older have coronary artery disease (CAD).
As number of people suffering from coronary artery and peripheral vascular diseases is rising steadily, the demand for percutaneous coronary intervention and peripheral vascular procedures will increase. This will lead to increase in adoption rate of stents, thereby propelling business growth throughout the forecast timeline.
Continuous rising cardiovascular disease incidences will have significant implication of healthcare resources, thereby accelerating industry growth in the region. Increasing number of chronic conditions such as cardiovascular disease and advancement in stents will drive industry growth in the future.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Stents market accounted for revenues worth USD 9.4 billion in 2023, record 4.7% CAGR to reach USD 14.0 billion by 2032, attributed to increasing adoption of minimally invasive techniques and rising number of cardiovascular surgeries.

The vascular stent segment is anticipated to reach USD 13 billion by 2032, driven by the growing burden of coronary artery disease and technological advancements for development of advanced product.

North America stents industry accounted for USD 2.1 billion in 2023 and is projected to record impressive growth through 2032, owing to high prevalence of cardiovascular diseases, such as coronary artery disease and peripheral artery disease.

Abbott Laboratories, B. Braun Melsungen AG, Biosensors International Group, Biotronik SE & Co. KG, Boston Scientific Corporation, Becton, Dickinson and Company, Elixir Medical Corporation, Medtronic Plc, Meril Life Science, MicroPort Scientific Corporation, and Stryker Corporation.